The coronavirus disease 2019 (COVID-19) pandemic has had enormous implications for the care of patients with chronic liver disease (CLD), cirrhosis, and liver transplant (LT). Clinical outcomes of COVID-19 vary in patients with CLD and cirrhosis compared to healthy controls, and in patients with LT compared to patients without LT. Several special considerations apply to the approach to vaccination and treatment in patients with CLD and LT. The practice of liver transplantation has also been heavily impacted by the pandemic, including persistent reductions in living donor LT and increases in LT for an indication of alcohol-related liver disease. Recent medical society guidelines strive to standardize severe acute respiratory syndrome coronavirus 2 testing in donors and recipients and the approach to transplantation after recovered from COVID-19 infection, but certain controversies remain.

中文翻译：

---

肝病和肝移植患者中的 COVID-19：临床意义、预防和管理。

2019 年冠状病毒病 (COVID-19) 大流行对慢性肝病 (CLD)、肝硬化和肝移植 (LT) 患者的护理产生了巨大影响。与健康对照者相比，患有 CLD 和肝硬化的患者以及患有 LT 的患者与未患有 LT 的患者相比，COVID-19 的临床结果有所不同。对于 CLD 和 LT 患者的疫苗接种和治疗方法，有一些特殊的考虑因素。肝移植的实践也受到了这一流行病的严重影响，包括活体捐献者 LT 的持续减少和酒精相关肝病指征的 LT 的增加。最近的医学会指南致力于规范供体和受者的严重急性呼吸综合征冠状病毒 2 检测以及从 COVID-19 感染恢复后的移植方法，但仍然存在某些争议。